Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc.

February 19, 2010 11:00 ET

Notice of Thallion Pharmaceuticals Fiscal 2009 Year End Conference Call

- Fourth quarter and year end financial results to be released on February 23, 2010 -

MONTREAL, QUEBEC--(Marketwire - Feb. 19, 2010) - Thallion Pharmaceuticals Inc. (TSX:TLN) will release its fourth quarter and year end financial results for 2009 on Tuesday, February 23, 2010 after 4:00 PM Eastern Time. The Company will subsequently hold a conference call on Tuesday, February 23, 2010 at 4:30 PM Eastern Time hosted by Dr. Allan Mandelzys, Chief Executive Officer and Mr. Michael Singer, Chief Financial Officer. A question and answer session will follow the corporate update.

DATE: February 23, 2010
TIME: 4:30 PM Eastern Time
DIAL IN NUMBER: 647-427-7450 or 888-231-8191
TAPED REPLAY: 416-849-0833 or 800-642-1687

A live audio webcast of the conference call will be available by visiting the Company's website at Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast.

About Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc. (TSX:TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's clinical programs include Shigamabs® and TLN-4601, a novel anti-cancer therapy. Shigamabs® is a dual antibody product for the treatment of Shiga toxin producing E. coli bacterial infections which is ready to begin a Phase II clinical program. Additional information about Thallion can be obtained at

Forward-Looking Statements
This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect Thallion's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the obtaining of court and other regulatory approvals and consents, the satisfaction of closing conditions, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in Thallion's ongoing filings with the Canadian securities regulatory authorities which filings can be found at Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Thallion undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

Contact Information